Novo Nordisk's Global Gambit: Price Cuts and New Doses to Defend a Slumping Share

Novo Nordisk slashes prices in India, launches Wegovy HD in the US, and gets EMA storage relief to counter generic pressure and a falling stock price.

Novo Nordisk’s stock, down roughly 28% since the start of the year, is under intense pressure from generic competition and a sobering financial outlook. The Danish pharmaceutical giant is now launching a multi-pronged counterattack, combining aggressive pricing in emerging markets with a key product launch in the United States, as investors await crucial first-quarter results.

In a significant operational win for its European business, the European Medicines Agency (EMA) relaxed storage rules for the weight-loss injection Wegovy this week. The drug can now be transported for up to 48 hours at temperatures reaching 30 degrees Celsius, eliminating the previous requirement for an unbroken cold chain. This change reduces packaging needs and substantially cuts distribution costs for pharmacies and online partners, giving Wegovy a unique logistical advantage as the only GLP-1 weight-loss drug in Europe with this approval.

This cost-saving measure is timely, as the company faces severe pricing pressures elsewhere. The patent for semaglutid expired in India in March, triggering a flood of cheaper generic alternatives that captured 33% of the market by that month. To defend its position, Novo Nordisk slashed prices effective April 1, cutting the entry-dose price of Ozempic by 36% and Wegovy by 48%. The strategy has so far stabilized its Indian market share at 25%, while rival Eli Lilly saw its share drop from 61% to 56%. Analysts view India's GLP-1 market as a long-term growth opportunity, potentially expanding to 50 billion rupees by 2030 due to rising obesity and diabetes rates.

Simultaneously, the company is pushing forward in the critical U.S. market. On April 7, Novo Nordisk confirmed the nationwide availability of Wegovy HD, a 7.2 mg semaglutid injection that is the highest approved dose. In the STEP UP clinical trial, patients achieved an average weight loss of 20.7%, with about one-third losing more than 25% of their body weight. The FDA fast-tracked its approval via the Commissioner's National Priority Voucher program. The drug is produced in Clayton, North Carolina, and is available through over 70,000 pharmacies and select telehealth providers, intensifying competition with Eli Lilly.

Pricing in the U.S. follows a two-tier strategy: cash-paying customers are charged approximately $399 monthly for the 7.2 mg dose, while those with private insurance may access savings programs bringing the cost down to as low as $25 per month.

Beyond commercial maneuvers, Novo Nordisk continues to support its share price through a buyback program. By April 1, the company had repurchased approximately 9.97 million B shares at an average price of 259.47 Danish kroner, for a total transaction volume of about 2.59 billion kroner. The overall program is authorized for up to 15 billion kroner within a twelve-month period starting February 2026.

The broader context remains challenging. The stock plunged around 15% in February after the company issued a downgraded annual forecast, briefly triggering a trading halt. For 2026, Novo Nordisk anticipates a sales decline of between 5% and 13%. All eyes are now on the first-quarter report due May 6. Analysts, including those at UBS which estimates a gross margin of 79%, will scrutinize whether strong volume growth can offset the impact of global price reductions. The performance of Wegovy HD, the ongoing U.S. rollout of an oral pill, and the stabilized position in India are the three levers the company is counting on to steer through a turbulent period.